3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Colonic Neoplasms in 1 studies
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.
Colonic Neoplasms: Tumors or cancer of the COLON.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rice, PL | 1 |
| Peters, SL | 1 |
| Beard, KS | 1 |
| Ahnen, DJ | 1 |
1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Colonic Neoplasms
| Article | Year |
|---|---|
Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Butadienes; Colonic Neoplasms; Cyclic GMP-Dependent | 2006 |